Cetuximab antibody | AbD19830_hIgG1
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti cetuximab (clone AbD19830_hIgG1) at a concentration of 2 μg/ml and QuantaBlu™ fluorogenic peroxidase substrate
A microtiter plate was coated over night with human IgG1/kappa, human IgG1/lambda, rituximab or cetuximab at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, detection was performed using Human anti cetuximab (clone AbD19830_hIgG1 in a monovalent format) titrated to the given concentrations in PBST+10% human serum, followed by Mouse anti histidine tag:HRP (MCA5995P) in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate
A microtitre plate was coated over night with cetuximab at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of Human anti cetuximab antibodies, clone AbD19830_hIgG1 (HCA221, green line), clone AbD19834_hIgG1 (HCA222, blue line) or clone AbD19815_hIgG1 (HCA223, red line). Detection was performed using HRP-conjugated cetuximab followed by QuantaBlu™ fluorogenic peroxidase substrate. HRP-conjugation of the cetuximab used in this assay was performed using a LYNX Rapid HRP Conjugation Kit®
A microtiter plate was coated over night with Human anti cetuximab (clone AbD19834, HCA220) at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of cetuximab. Detection was performed using HRP-conjugated Human anti cetuximab (clone AbD19830_hIgG1) at a concentration of 2 µg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate
A microtiter plate was coated over night with EGFR at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, a pre-incubated mixture of cetuximab (CTX, 0.3 µg/ml) plus increasing concentrations of Human anti cetuximab antibodies (HCA221, HCA220, HCA223 or the non-inhibitory HCA228) was added. For this assay, HCA221, HCA223 and HCA228 were used in their monovalent Fab format. Free cetuximab, still capable of binding to the EGFR-coated plate, was detected using Goat anti Human IgG F(ab')2:HRP (STAR126P)
A microtitre plate was coated over night with cetuximab at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of Human anti cetuximab antibodies, clone AbD19830_hIgG1 (HCA221, green line), clone AbD19834_hIgG1 (HCA222, blue line) or clone AbD19815_hIgG1 (HCA223, red line). Detection was performed using HRP-conjugated cetuximab followed by QuantaBlu™ fluorogenic peroxidase substrate. HRP-conjugation of the cetuximab used in this assay was performed using a LYNX Rapid HRP Conjugation Kit®
Human anti Cetuximab:HRP
Anti-cetuximab antibody is a recombinant, neutralizing anti-idiotypic antibody in full IgG1 format; it is ideal for bioanalytical assay development for cetuximab and biosimilars. It is suitable as a detection antibody in PK bridging ELISA format with HCA220 for an assay to detect free drug.
Human anti Cetuximab
Anti-cetuximab antibody is a recombinant, neutralizing anti-idiotypic antibody in full IgG1 format; it is ideal for bioanalytical assay development for cetuximab and biosimilars. It is suitable as a detection antibody in PK bridging ELISA format with HCA220 for an assay to detect free drug.
- Product Type
- Monoclonal Antibody
- Clone
- AbD19830_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| HCA221P | E | 0.1 mg |
|
|
| HCA221 | E | 0.1 mg |
|
Human anti Cetuximab, clone AbD19830_hIgG1, is an anti-idiotypic antibody that binds specifically to cetuximab and inhibits the binding of the drug to its target. Human anti Cetuximab, clone AbD19830_hIgG1 can be used to measure the levels of cetuximab and biosimilar products using bioanalytical assays.
In the HRP-conjugated format clone AbD19830_hIgG1 is ideal for use as detection antibody in pharmacokinetic (PK) assays. It is a fully human antibody and therefore may also be used as a calibrator in immune response assays to measure the anti-drug-antibody (ADA) response in patient sera.
Cetuximab (brand name Erbitux®) is a chimeric monoclonal antibody drug (IgG1/kappa) approved for treatment of KRAS wild-type metastatic colorectal cancers and squamous cell carcinoma of the head and neck. This therapeutic antibody, directed against the Epidermal Growth Factor Receptor (EGFR), inhibits tumor cell proliferation by blocking the interaction of Epidermal Growth Factor (EGF) with its receptor.
View a summary of all anti cetuximab antibodies.
In the HRP-conjugated format clone AbD19830_hIgG1 is ideal for use as detection antibody in pharmacokinetic (PK) assays. It is a fully human antibody and therefore may also be used as a calibrator in immune response assays to measure the anti-drug-antibody (ADA) response in patient sera.
Cetuximab (brand name Erbitux®) is a chimeric monoclonal antibody drug (IgG1/kappa) approved for treatment of KRAS wild-type metastatic colorectal cancers and squamous cell carcinoma of the head and neck. This therapeutic antibody, directed against the Epidermal Growth Factor Receptor (EGFR), inhibits tumor cell proliferation by blocking the interaction of Epidermal Growth Factor (EGF) with its receptor.
View a summary of all anti cetuximab antibodies.
Product Details
- Product Form
- Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
- Product Form
- Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Cetuximab.
- Affinity
- The monovalent intrinsic affinity of HCA221 was measured as KD=1.7 nM by real time, label free molecular interaction analysis on immobilized cetuximab.
- Approx. Protein Concentrations
- Total protein concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.5 mg/ml
Storage Information
- Storage
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Cetuximab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used as a detection reagent in a bridging ELISA for PK assay development together with HCA220 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug - ELISA
- This product may be used in a direct ELISA or as a bridging reagent in ADA assays. Following HRP-conjugation, this product can also be used as a detection reagent in a bridging ELISA for PK assay development together with HCA220 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
Protocol: ADA bridging ELISA
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Cetuximab | HCA220 | E | 0.1 mg |
|
|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Cetuximab | HCA220 | E | 0.1 mg |
|
|
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody |
Product Specific References
Further Reading
-
Gomez, D. et al. (2013) Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier?
Int J Surg. 11 (7): 507-13.
